Alastair Gray1, Philip Clarke, Andrew Farmer, Rury Holman. 1. Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford OX3 7LF. alastair.gray@ihs.ox.ac.uk
Abstract
OBJECTIVE: To estimate the incremental cost of implementing policies for intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England. DESIGN: Extrapolation of resource use and cost data derived from a randomised controlled trial. SETTING: General practice, outpatient care, and inpatient care. POPULATION: Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England. MAIN OUTCOME MEASURES: Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation. RESULTS: The incremental net annual cost of implementing intensive control of blood glucose and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be pound 100.5m ($156m; euro;159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied in sensitivity analyses from pound 67m to pound 121m. CONCLUSIONS: Policies to improve control of blood glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost effective. The total cost represents a small fraction of the NHS's spending plans.
RCT Entities:
OBJECTIVE: To estimate the incremental cost of implementing policies for intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England. DESIGN: Extrapolation of resource use and cost data derived from a randomised controlled trial. SETTING: General practice, outpatient care, and inpatient care. POPULATION: Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England. MAIN OUTCOME MEASURES: Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation. RESULTS: The incremental net annual cost of implementing intensive control of blood glucose and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be pound 100.5m ($156m; euro;159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied in sensitivity analyses from pound 67m to pound 121m. CONCLUSIONS: Policies to improve control of blood glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost effective. The total cost represents a small fraction of the NHS's spending plans.
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank Journal: Cochrane Database Syst Rev Date: 2015-01-31
Authors: James Lightwood; Kirsten Bibbins-Domingo; Pamela Coxson; Y Claire Wang; Lawrence Williams; Lee Goldman Journal: Am J Public Health Date: 2009-10-15 Impact factor: 9.308
Authors: Mark A Hlatky; Derek B Boothroyd; Kathryn A Melsop; Laurence Kennedy; Charanjit Rihal; William J Rogers; Lakshmi Venkitachalam; Maria M Brooks Journal: Circulation Date: 2009-11-17 Impact factor: 29.690